Alves J C, Santos A, Filipe Ana, Carreira L Miguel
Divisão de Medicina Veterinária, Guarda Nacional Republicana (GNR). Rua Presidente Arriaga, 9 1200-771 Lisbon, Portugal; Faculty of Veterinary Medicine, Lusófona University, Lisbon, Portugal; CECAV - Animal and Veterinary Research Center, Lusófona University, Lisbon, Portugal; MED - Mediterranean Institute for Agriculture, Environment and Development, Instituto de Investigação e Formação Avançada, Universidade de Évora, Pólo da Mitra, Ap. 94, 7006-554 Évora, Portugal.
Divisão de Medicina Veterinária, Guarda Nacional Republicana (GNR). Rua Presidente Arriaga, 9 1200-771 Lisbon, Portugal.
Res Vet Sci. 2024 Nov;180:105422. doi: 10.1016/j.rvsc.2024.105422. Epub 2024 Sep 27.
We aimed to evaluate the effect of the intravenous (IV) administration of blood cell secretome (BCS) compared to its intra-articular (IA) administration. In this cross-over study, ten dogs with bilateral hip osteoarthritis were initially assigned to an IA group (IAG). After a 180-day follow-up, the same 10 animals were assigned to an IV group (IVG). IAG received a single IA administration of 3 ml of BCS per hip joint, and IVG received a single 6 ml IV administration of BCS. Following each treatment, follow-up was conducted on days 0, 8, 15, 30, 60, 90, 120, 150, and 180. In each follow-up, copies of the Canine Brief Pain Inventory (divided into pain interference score - PIS and Pain Severity Score - PSS), Liverpool Osteoarthritis in Dogs (LOAD), and Canine Orthopedic Index (COI, divided into function, gait, stiffness, and quality of life) were obtained. Results were analyzed with the Mann-Whitney test, and Kaplan-Meier estimators were calculated and compared, p < 0.05. The animals had a mean age of 7.6 ± 2.9 years and bodyweight of 27.8 ± 3.6 kg. Seven hips were classified as moderate osteoarthritis, and three as severe. No differences were found between groups from days 0 to +60d, with both groups showing clinically significant improvements. Improvements in the IAG lasted up to +120d. Kaplan-Meier estimators showed that dogs in IAG took longer to record the considered events. IVG also showed positive clinically significant results with different instruments. IV administration of BCS can improve the overall condition of dogs with hip OA, but the IA administration produces longer-lasting results.
我们旨在评估静脉注射（IV）血细胞分泌组（BCS）与关节内（IA）注射相比的效果。在这项交叉研究中，10只患有双侧髋关节骨关节炎的犬最初被分配到IA组（IAG）。经过180天的随访后，同样的10只动物被分配到IV组（IVG）。IAG每侧髋关节接受一次3毫升BCS的IA注射，IVG接受一次6毫升BCS的IV注射。每次治疗后，在第0、8、15、30、60、90、120、150和180天进行随访。在每次随访中，获取犬简短疼痛量表（分为疼痛干扰评分 - PIS和疼痛严重程度评分 - PSS）、犬类骨关节炎利物浦评分（LOAD）以及犬类骨科指数（COI，分为功能、步态、僵硬程度和生活质量）的副本。结果采用曼 - 惠特尼检验进行分析，并计算和比较卡普兰 - 迈耶估计值，p < 0.05。这些动物的平均年龄为7.6 ± 2.9岁，体重为27.8 ± 3.6千克。七个髋关节被分类为中度骨关节炎，三个为重度。在第0天至 +60天期间，两组之间未发现差异，两组均显示出临床上的显著改善。IAG组的改善持续到 +120天。卡普兰 - 迈耶估计值表明，IAG组的犬记录所考虑事件的时间更长。IVG组使用不同工具也显示出临床上的积极显著结果。静脉注射BCS可改善患有髋关节OA的犬的整体状况，但关节内注射产生的效果持续时间更长。
